###begin article-title 0
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
Germline mutations in BRCA1 or BRCA2 genes have been demonstrated to increase the risk of developing breast cancer. Conversely, the impact of BRCA mutations on prognosis and survival of breast cancer patients is still debated. In this study, we investigated the role of such mutations on breast cancer-specific survival among patients from North Sardinia.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Among incident cases during the period 1997-2002, a total of 512 breast cancer patients gave their consent to undergo BRCA mutation screening by DHPLC analysis and automated DNA sequencing. The Hakulinen, Kaplan-Meier, and Cox regression methods were used for both relative survival assessment and statistical analysis.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 366 372 366 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
In our series, patients carrying a germline mutation in coding regions and splice boundaries of BRCA1 and BRCA2 genes were 48/512 (9%). Effect on overall survival was evaluated taking into consideration BRCA2 carriers, who represented the vast majority (44/48; 92%) of mutation-positive patients. A lower breast cancer-specific overall survival rate was observed in BRCA2 mutation carriers after the first two years from diagnosis. However, survival rates were similar in both groups after five years from diagnosis. No significant difference was found for age of onset, disease stage, and primary tumour histopathology between the two subsets.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
In Sardinian breast cancer population, BRCA2 was the most affected gene and the effects of BRCA2 germline mutations on patients' survival were demonstrated to vary within the first two years from diagnosis. After a longer follow-up observation, breast cancer-specific rates of death were instead similar for BRCA2 mutation carriers and non-carriers.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1072 1073 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
The breast cancer is a complex disease with high biological heterogeneity and wide spectrum of responsiveness to different treatments. The well-established prognostic factors currently used into the management of patients with breast carcinoma include the disease stage (which takes into account tumour size, axillary lymph node involvement, and distant tumour dissemination) as well as the histological type, the degree of differentiation (tumour grade), the proliferation index, and the receptor status [estrogen receptor (ER), progesterone receptor (PR), and, recently, HER2] of the primary tumours [1]. Among them, the expression levels of hormone receptors seem to better predict the breast cancer response to different therapeutic strategies. More in general, the assessment of some molecular mechanisms responsible for the mammary tumourigenesis and studies on molecular profiling allowed to identify several biomarkers which may be helpful to pathologically classify breast cancer lesions into subtypes with different prognostic and clinico-pathologic behaviours [2,3].
###end p 11
###begin p 12
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 516 521 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 549 554 549 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
Mutations in the BRCA1 and BRCA2 tumour suppressor genes have been associated with the breast cancer risk among families with strong recurrence of the disease [4-9]. Vast majority of studies has shown a highly increased risk of developing breast cancer in BRCA1 or BRCA2 mutation carriers [4-7] with also a greater incidence of a second contra-lateral tumour [4,5,10]. However, majority of breast cancers occur sporadically in individuals with little or no family history, for whom no clear role of the mutations in BRCA genes has emerged. Overall, BRCA mutations are responsible for 30-60% of the hereditary cases and have a prevalence of about 5% in the general population and about 25% in the families with history of breast cancer [9].
###end p 12
###begin p 13
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 511 516 511 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 714 719 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 815 821 815 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 951 956 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1053 1058 1053 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 1109 1111 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1194 1199 1194 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1374 1379 1374 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
###xml 873 881 <span type="species:ncbi:9606">patients</span>
###xml 1361 1366 <span type="species:ncbi:9606">women</span>
Analogously, several studies have investigated the possible effects of BRCA mutations on clinical and pathologic characteristics of breast cancer as well as on prognosis and survival rates of the patients, but the results were inconclusive. Some of these studies have demonstrated that BRCA1 mutation carriers develop cancer with a high proliferation index and low expression of estrogen receptors [11,12]. Moreover, a higher proliferation index has been reported in all breast cancer sporadic cases carrying a BRCA germline mutation (regardless of the gene involved) in comparison to the patients with wild-type BRCA [13-15]. Conversely, other authors observed no difference in histological tumour features among BRCA2-positive familial cases and sporadic cases [16]. Regarding the relationship with the survival, BRCA1 mutation carriers showed either a poor prognosis in patients with negative lymph nodes [17] or a worse outcome in comparison with BRCA2-positive cases [18,19]. Other investigators did not find any significant survival difference in BRCA mutation carriers compared with non-carrier cases [20,21]; moreover, breast cancer specific mortality rates have been found similar for BRCA mutation carriers and non-carriers in Jewish population [22]. Nevertheless, a better assessment of the role on survival and prognosis could be also important for women with a BRCA mutation who face a decision between preventive surgery and intensive surveillance.
###end p 13
###begin p 14
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 436 442 436 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 523 538 523 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2-8765delAG</italic>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1195 1200 1195 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 1392 1398 1392 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 902 907 <span type="species:ncbi:9606">women</span>
###xml 1313 1321 <span type="species:ncbi:9606">patients</span>
###xml 1559 1567 <span type="species:ncbi:9606">patients</span>
In Sardinia, whose population is genetically homogeneous due to the fact that it is relatively isolated and with high rate of inbreeding, the contribution of BRCA mutations to the population incidence of breast cancer has been evaluated by our group in recent past years [23-25]. Three deleterious BRCA germline mutations have been observed in about 15% families and in about 3% non-familial breast cancer patients from North Sardinia (BRCA2 mutations were the most prevalent BRCA sequence variations and a single variant, BRCA2-8765delAG, was the most recurrent mutation with a founder effect in our population) [23-25]. In North Sardinia, breast cancer represents the principal death-causing malignancy, with an incidence rate quite comparable with that observed in Western countries (standardized rate, 95 per 100.000 inhabitants per year); the median age of onset for breast cancer among Sardinian women is 65 years [26]. Based on the existence of an official cancer registry, which has recorded all malignancies diagnosed into the population of the province of Sassari from 1992 to 2003 [26], the objective of the present study was to investigate the relationship between the occurrence of BRCA mutations and the main standardized prognostic factors as well as the overall survival rates among breast cancer patients from North Sardinia. Specifically, we compared survival rates between BRCA2 mutation carriers and non-carriers while adjusting for demographic and clinically-recognized prognostic factors in a homogenous group of Sardinian breast cancer patients.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients' selection
###end title 16
###begin p 17
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
Among 1,835 incident cases during the period 1997-2002 [with 140 (8%) tumour-specific deaths], we selected all consecutive patients with histologically-proven diagnosis of malignant breast cancer (regardless of factors which may influence prognosis: age, family history, disease stage, or type of treatment). Among them, 512 patients gave their consent to undergo genetic analysis for detection of BRCA mutations on germline DNA from peripheral blood. For such cases, the collected information included the disease stage at diagnosis, the expression levels of estrogen and progesterone receptors, and the occurrence of a second cancer. All information have been verified through analysis of the hospital records; all cancer diagnoses were confirmed by pathology reports.
###end p 17
###begin p 18
The study was reviewed and approved by the ethical review boards of both Institutions (University of Sassari and A.S.L.1 of Sassari).
###end p 18
###begin title 19
Mutation screening
###end title 19
###begin p 20
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 374 380 374 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 170 177 <span type="species:ncbi:9606">patient</span>
For the BRCA1 and BRCA2 genetic testing, all patients were informed about the aims and limits of the mutation analysis and blood samples were collected after obtaining a patient's written consent (in any case, documentation of counselling was carefully evaluated prior to genetic testing). As previously described [23,24], genomic DNA samples were screened for mutations in BRCA1 and BRCA2 genes by a sequential combination of denaturing high-performance liquid chromatography (DHPLC) analysis and sequencing approach using an automated fluorescence-cycle sequencer (ABIPRISM 3100, Applied Biosystems, Foster City, CA).
###end p 20
###begin title 21
Statistical analysis
###end title 21
###begin p 22
###xml 493 501 <span type="species:ncbi:9606">patients</span>
The following variables and categories were defined and included in our analyses: pathological primary tumor size (pT), pathological nodal status (pN), presence of distant metastases (M), estrogen and progesteron receptor (ER and PR, respectively) status, age at diagnosis, and overall survival (calculated starting from the time of diagnosis to the date of death or to the end of our follow-up observation on December 31, 2004). Receptor status was not known in a fraction (about 30%) of the patients included into the study.
###end p 22
###begin p 23
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
The general mortality data were provided from official regional sources, and in some cases were drawn from the municipality rosters. The death probability was calculated on the mortality rate basis and expressed as the probability that an individual has, at beginning of the age class considered, to die before going to the next age class. The formula from life-table that assume a constant mortality rate within a given period was applied [27]. In this case, the age class was equal to one year, as required by the Hakulinen method for calculation of relative survival [28].
###end p 23
###begin p 24
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 149 158 149 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">eurocare </italic>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
The five-year relative survival figures were also computed following the Hakulinen method [28]; the 95% confidence limits were calculated using the "eurocare " confidence interval algorithm [29]. For the comparison of survival probabilities within the various subgroups, the cumulative relative survival adjusted for age was estimated using the technique proposed by Brenner and colleagues [29].
###end p 24
###begin p 25
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
The role of familiarity and BRCA status as genetic marker in cause-specific survival was investigated by Kaplan-Meier and Cox regression methods. All tests were computed by Stata Software.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Among the 512 breast cancer patients who gave their consent to participate to the study, 103 (20%) had a family history of breast cancer. Cases were classified as familial when at least three affected members (considering first- and second-degree relatives) were diagnosed with breast cancer.
###end p 27
###begin p 28
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 457 463 457 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 598 604 598 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 608 614 608 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 668 673 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 715 721 715 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 779 785 779 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 859 875 859 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2-8765delAG </italic>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 995 1000 995 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
Mutation analysis for all coding regions and splice boundaries of BRCA1 and BRCA2 genes was performed as previously described [24]. Briefly, germline DNA from breast cancer patients was screened by DHPLC analysis; all PCR products presenting an abnormal denaturing profile in comparison to the normal controls were sequenced using an automated approach. Taking into consideration the 103 familial cases, 2 (2%) and 20 (19%) presented a germline mutation in BRCA1 and BRCA2 genes, respectively. Among the remaining 409 patients classified as sporadic cases, 2 (0.5%) and 24 (6%) were found to carry BRCA1 and BRCA2 mutations, respectively. Overall, patients carrying a BRCA mutation were 48/512 (9%). In particular, BRCA1 mutations were detected in only 4/48 (8%) carriers, while BRCA2 mutations were identified in vast majority of them (44/48; 92%), with the BRCA2-8765delAG variant acting as a founder mutation [23-25]. Taking into account such a high preponderance of germline mutations, only BRCA2-positive cases were considered for statistical correlations in our series.
###end p 28
###begin p 29
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 301 307 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 343 347 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 441 445 437 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 579 585 575 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 722 723 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 741 747 737 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 830 838 <span type="species:ncbi:9606">patients</span>
The age of breast cancer onset was evaluated on the basis of the mutation status; 23/44 (52%) BRCA2 mutation positive and 188/464 (41%) BRCA2 mutation negative patients were 50 years or younger at the time of diagnosis (Table 1). Although the average age at diagnosis was younger in patients carrying BRCA2 mutations [23/44 (52%) </= 50 years vs. 21/44 (48%) > 50 years] than in cases with no detectable mutation [188/464 (41%) </= 50 years vs. 276/464 (59%) > 50 years], such a difference was not statistically significant. Using Pearson's Chi-Squared test, the occurrence of a BRCA2 mutation was evaluated for association with several pathological parameters: pT, pN, M, or, when available, ER and PR. As shown in Table 2, distribution of BRCA2 mutation carriers and non-carriers was quite identical in the different subsets of patients according to such pathological parameters (thus, no statistically significant correlation was observed - not shown).
###end p 29
###begin p 30
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
Distribution of patients according to BRCA2 mutation status and age of onset
###end p 30
###begin p 31
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Taking into consideration the primary tumour morphology, 348 (68%) ductal carcinomas, 62 (12%) lobular carcinomas, and 102 (20%) other histological types were registered. The BRCA2 mutations were more prevalent in lobular (7/62; 11%) than in ductal carcinomas (20/348; 6%); again, differences were not statistically significant.
###end p 31
###begin p 32
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 365 371 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 478 484 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 730 731 730 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 801 807 801 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 930 936 930 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1019 1020 1019 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1100 1101 1100 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
The five-year survival rate was 81% (80%, adjusted by age) among BRCA2 mutation carriers and 91% (92%, adjusted by age) among patients negative for BRCA2 mutations. Overall, the five-year relative survival rate for breast cancer cases from our series was 85%. Evaluation of the overall survival curves using the Kaplan-Meier method indicated that patients carrying BRCA2 mutations presented a lower breast cancer-specific survival in comparison with those resulted negative for BRCA2 mutations, within the first two years from diagnosis (Figure 1). Considering the entire observation period of five years from diagnosis, the survival curves tended to merge with no significant difference in outcome between the two groups (Figure 1). Furthermore, no difference in survival among familial and sporadic BRCA2 mutated cases was observed (not shown). As estimated by Cox regression analysis, the hazard ratio of patients positive for BRCA2 mutations was found to be 0.7 (95% CI, 0.46-1.37), after adjustment by age (Figure 2), and about 0.8 (95% CI, 0.48-1.62), after adjustment by disease stage (Figure 3). Hazard ratios were quite identical for both subsets when adjusted for tumour grade (0.82; 95% CI, 0.53-0.98) and receptor status (0.85; 95% CI, 0.64-0.97) (not shown).
###end p 32
###begin p 33
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overall survival curves based on the Kaplan-Meier method</bold>
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Overall survival curves based on the Kaplan-Meier method. Comparison between observed and predicted survival data for each subset of patients (with or without BRCA2 mutations) is reported.
###end p 33
###begin p 34
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 0 134 0 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative five-year survival for breast cancer patients with or without <italic>BRCA2 </italic>mutations (BRCA+/-), adjusted by age according to Brenner</bold>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Relative five-year survival for breast cancer patients with or without BRCA2 mutations (BRCA+/-), adjusted by age according to Brenner.
###end p 34
###begin p 35
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 0 193 0 193 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative five-year survival for breast cancer patients according to (A) localized disease (stage 1&#8211;2) or (B) metastatic disease (stage 3&#8211;4), and presence or absence of <italic>BRCA2 </italic>mutations (BRCA+/-)</bold>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Relative five-year survival for breast cancer patients according to (A) localized disease (stage 1-2) or (B) metastatic disease (stage 3-4), and presence or absence of BRCA2 mutations (BRCA+/-).
###end p 35
###begin p 36
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 493 499 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 613 619 613 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
Finally, multivariate Cox regression analysis was performed considering all variables (pT, pN, M, ER, PR, and BRCA2 mutations). The presence of metastases was the only parameter with a significant impact on prognosis (p < 0.001; hazard ratio, 8.939; 95% CI, 4.68-17.1). However, such a prognostic factor was not able to exert a confounding effect on mutation-based survival curves due to the low number of patients with distant metastases (33/508; 6%), who even showed a similar prevalence of BRCA2 mutation-negative (30/464; 6%) and mutation-positive (3/44; 7%) cases (see Table 2). No other association between BRCA2 mutation status and overall survival was observed for the remaining variables.
###end p 36
###begin p 37
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Distribution of BRCA2 cases according to the TNM and receptor status
###end p 37
###begin title 38
Discussion and conclusion
###end title 38
###begin p 39
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 354 360 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 363 369 363 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 81 86 <span type="species:ncbi:9606">women</span>
Breast cancers carrying BRCA1 or BRCA2 germline mutations often occur in younger women as well as present a high tumour grade and/or lack of expression of estrogen/progesterone receptors (mostly, among BRCA1-positive tumours) [11-16,30-32]. Although these features have been associated with a poor prognosis, the relationship between the occurrence of a BRCA1 or BRCA2 mutation and the effect on overall survival is still controversial [17-22,31,33-35].
###end p 39
###begin p 40
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 514 520 514 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 237 242 <span type="species:ncbi:9606">women</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 458 463 <span type="species:ncbi:9606">women</span>
In this study, we tried to clarify the role of BRCA mutations on the outcome of breast cancer patients from North Sardinia, where an official cancer registry is available [26]. In particular, we evaluated the 5-year survival rates among women who had received the diagnosis of breast cancer from 1997 to 2002 and gave their consent to undergo a BRCA genetic testing. Among the 508 analyzed patients, we assessed the breast cancer-specific survival rates for women with (44 cases; 9%) or without (464 cases; 91%) a BRCA2 germline mutation.
###end p 40
###begin p 41
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 407 413 407 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 809 815 809 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 849 855 849 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 997 998 997 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1003 1004 1003 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1078 1084 1078 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1271 1273 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1274 1276 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1421 1427 1421 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 873 881 <span type="species:ncbi:9606">patients</span>
Using the Kaplan-Meier method, the survival rate of patients with a positive BRCA2 genetic test was lower than that of patients with negative genetic tests within the first two years after diagnosis in our series. However, the two survival curves tended to merge at the end of five years from diagnosis (see Figure 1). This trend may indeed account for the absence of significance of the Cox regression for BRCA2 status, due to the failure of proportionality of hazards (a situation in which calculation of a total hazard ratio with the Cox model is unsuitable). The relative survival of the entire Sardinian series at five years from diagnosis is slightly below the average survival rate observed in breast cancer cases from the other Italian regions [17]; moreover, it always remains lower in the subset of BRCA2 mutation carriers than in that of BRCA2 mutation-negative patients, regardless the adjustments according to the different prognostic parameters in multivariate analysis (see Figures 2 and 3). Indeed, the relative survival seems to be worse in cases with positive BRCA2 genetic tests, even after adjustment for age of onset (which represents one of the factors with the greatest influence on cancer prognosis, according to the studies in other populations [34-36]). Although survival is also deeply influenced by disease stage at the time of diagnosis, we observed no significant difference between the two BRCA2 subsets after stratification by stage.
###end p 41
###begin p 42
###xml 321 327 321 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
Although our study has a number of limitations mainly due to the fact that we identified only a limited fraction (44/508; 9%) of mutation carriers and, thus, the subgroup analyses relied on a small number of subjects, we can conclude that a prolonged follow-up observation seems to minimize the effect of the presence of BRCA2 germline mutations on prognosis among breast cancer patients from Sardinian population.
###end p 42
###begin p 43
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 67 72 <span type="species:ncbi:9606">women</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
Our findings are consistent with data recently reported in Israeli women of Ashkenazi Jewish ancestry (who present a high prevalence of hereditary breast cancer and BRCA founder mutations) [22] as well as in a Dutch series of BRCA1-associated breast carcinoma patients [37]. In both studies, the breast cancer-specific survivals for carriers and noncarriers of BRCA mutations were similar, even considering a longer period of observation (ten years) from diagnosis [22,37]. On the basis of these results, one could speculate that additional factors may influence the prognosis in such patients.
###end p 43
###begin p 44
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 293 298 <span type="species:ncbi:9606">women</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
Search for prognostic factors in breast cancer patients is still a challenge; several lifestyle and environmental risk factors for breast cancer are being investigated. For example, evidence have been recently found that an increase in body mass index is associated with a poorer prognosis in women receiving diagnosis of breast cancer [36]. Probably, further studies toward the comprehension of the underlying interactions between all genetic and environmental factors could really improve the classification of the different subsets of patients who would be expected to have better or worse prognosis as well as to be more or less likely to respond to specific therapeutic interventions.
###end p 44
###begin title 45
Competing interests
###end title 45
###begin p 46
The authors declare that they have no competing interests.
###end p 46
###begin title 47
Authors' contributions
###end title 47
###begin p 48
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
MB participated to the design of the study and performed statistical analyses. RC participated to analysis and interpretation of data. VC participated to statistical analysis. OS participated to analysis and interpretation of data. DP performed the data management. AC participated to patients' collection and performed some screening analyses. FT participated to patients' collection. MP participated to mutation analysis. GrP performed mutation screening. GiP conceived of the study and drafted the manuscript. All authors read and approved the final manuscript.
###end p 48
###begin title 49
Pre-publication history
###end title 49
###begin p 50
The pre-publication history for this paper can be accessed here:
###end p 50
###begin p 51

###end p 51
###begin title 52
Acknowledgements
###end title 52
###begin p 53
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Authors are grateful to patients and families for their important contribution to this study. Work was funded by Regione Autonoma della Sardegna, Ricerca Finalizzata Ministero della Salute, Associazione Italiana Ricerca sul Cancro (AIRC), and Associazione UMANA Onlus.
###end p 53
###begin article-title 54
Breast cancer prognostication and prediction: are we making progress?
###end article-title 54
###begin article-title 55
Gene expression profiling predicts clinical outcome of breast cancer
###end article-title 55
###begin article-title 56
###xml 101 106 <span type="species:ncbi:9606">human</span>
Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors
###end article-title 56
###begin article-title 57
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
###end article-title 57
###begin article-title 58
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers
###end article-title 58
###begin article-title 59
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
###end article-title 59
###begin article-title 60
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium
###end article-title 60
###begin article-title 61
Institut Curie Breast Cancer Study Group. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy
###end article-title 61
###begin article-title 62
Screening for hereditary breast cancer
###end article-title 62
###begin article-title 63
###xml 102 107 <span type="species:ncbi:9606">women</span>
Hereditary Breast Cancer Clinical Study Group. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group
###end article-title 63
###begin article-title 64
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers
###end article-title 64
###begin article-title 65
Clinico-pathological characteristics of BRCA1 and BRCA2-related breast cancer
###end article-title 65
###begin article-title 66
Histopathology of BRCA1- and BRCA2-associated breast cancer
###end article-title 66
###begin article-title 67
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers
###end article-title 67
###begin article-title 68
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
###end article-title 68
###begin article-title 69
The Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
###end article-title 69
###begin article-title 70
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
###end article-title 70
###begin article-title 71
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
###end article-title 71
###begin article-title 72
Familial invasive breast cancers: worse outcome related to BRCA1 mutations
###end article-title 72
###begin article-title 73
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden
###end article-title 73
###begin article-title 74
Survival and prognostic factors in BRCA1-associated breast cancer
###end article-title 74
###begin article-title 75
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations
###end article-title 75
###begin article-title 76
BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling
###end article-title 76
###begin article-title 77
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian breast cancer patients through a hospital-based screening
###end article-title 77
###begin article-title 78
Origin and distribution of the BRCA2-8765delAG mutation in breast cancer
###end article-title 78
###begin article-title 79
Cancer incidence in Sassari Province (1998-2002)
###end article-title 79
###begin article-title 80
###xml 47 54 <span type="species:ncbi:9606">patient</span>
Cancer survival corrected for heterogeneity in patient withdrawal
###end article-title 80
###begin article-title 81
Methods of data analysis
###end article-title 81
###begin article-title 82
Age adjustment of cancer survival rates: methods, point estimates and standard errors
###end article-title 82
###begin article-title 83
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor
###end article-title 83
###begin article-title 84
Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases
###end article-title 84
###begin article-title 85
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study
###end article-title 85
###begin article-title 86
###xml 38 50 38 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1, BRCA2</italic>
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland
###end article-title 86
###begin article-title 87
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Survival and recurrence after breast cancer in BRCA1/2 mutation carriers
###end article-title 87
###begin article-title 88
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status
###end article-title 88
###begin article-title 89
Risk factors for the incidence of breast cancer: do they affect survival from the disease?
###end article-title 89
###begin article-title 90
Survival and prognostic factors in BRCA1-associated breast cancer
###end article-title 90

